. Author manuscript; available in PMC: 2011 Aug 30.

Published in final edited form as: Int J Pharm. 2010 Jul 1;396(1-2):111–118. doi: 10.1016/j.ijpharm.2010.06.039

Table 3.

ASBT inhibition and uptake kinetics of CDCA-lysine-niacin and CDCA-lysine-ketoprofen.

Conjugate	K_i (μM)	K_t (μM)	normJ_max^a	P_p ×10⁶(cm/s)
CDCA-lysine-niacin	12.9 (±2.6)	8.22 (±3.63)	0.0917 (±0.0102)	0.367(±0.023)
CDCA-lysine-ketoprofen	15.6 (±2.7)	50.8 (±23.2)	1.87 (±0.36)	6.38(±0.44)

Data were summarized as mean (±SEM) of three measurements.

To accommodate variation in ASBT expression levels across studies, J_max of each bile acid was normalized against taurocholate J_max from the same study yielding normJ_max.